Photodissociation of interstellar ArH+

Aims. Following the recent detection of 36ArH+ in the Crab nebula spectrum, we have computed the photodissociation rate of ArH+ in order to constrain the physical processes at work in this environment. Methods. Photodissociation cross sections of ArH+ are computed in an ab initio approach including explicit account of spin-orbit coupling. Results. We report the photodissociation cross section of ArH+ as a function of wavelength. Photodissociation probabilities are derived for different impinging radiation fields.The photodissociation probability of for a very small unshielded cloud surrounded on all sides by the unshielded InterStellar Radiation Field (ISRF) model described by Draine (1978) is equal to 9.9e-12 s-1 and 1.9e-9 s-1 in the Crab nebula conditions. The dependence on the visual extinction is obtained by using the Meudon Photon Dominated Region (PDR) code and corresponding analytical fits are provided. Conclusions. These data will help to produce a realistic chemical network to interpret the observations. Photodissociation of ArH+ is found to be moderate and the presence of this molecular ion is mainly dependent on the molecular fractionComment: 11 pages, 6 Figures, Accepted in Astronomy Astrophysic

Towards the electron EDM search. Theoretical study of PbF

We report ab initio relativistic correlation calculations of potential curves and spectroscopic constants for four lowest-lying electronic states of the lead monofluoride. We also calculated parameters of the spin-rotational Hamiltonian for the ground and the first excited states including P,T-odd and P-odd terms. In particular, we have obtained hyperfine constants of the $^{207}$Pb nucleus. For the $^2\Pi_{1/2}$ state $A_\perp=-6859.6$ MHz, $A_\|=9726.9$ MHz and for the A$^2\Sigma^+_{1/2}$ $A_\perp=1720.8$ MHz, $A_\|=3073.3$ MHz. Our values of the ground state hyperfine constants are in good agreement with the previous theoretical studies. We discuss and explain seeming disagreement in the sign of the constant $A_\perp$ with the recent experimental data. The effective electric field on the electron $E_{eff}$, which is important for the planned experiment to search for the electric dipole moment of the electron, is found to be 3.3 * 10^{10} V/cm

Towards the electron EDM search: Theoretical study of HfF+

We report first ab initio relativistic correlation calculations of potential curves for ten low-lying electronic states, effective electric field on the electron and hyperfine constants for the ^3\Delta_1 state of cation of a heavy transition metal fluoride, HfF^+, that is suggested to be used as the working state in experiments to search for the electric dipole moment of the electron. It is shown that HfF^+ has deeply bound ^1\Sigma^+ ground state, its dissociation energy is D_e=6.4 eV. The ^3\Delta_1 state is obtained to be the relatively long-lived first excited state lying about 0.2 eV higher. The calculated effective electric field E_eff=W_d|\Omega| acting on an electron in this state is 5.84*10^{24}Hz/(e*cm)Comment: 4 page

Configuration interaction calculation of hyperfine and P,T-odd constants on ^{207}PbO excited states for the electron EDM experiments

We report first configuration interaction calculations of hyperfine constants A_\parallel and the effective electric field W_d acting on the electric dipole moment of the electron, in two excited electronic states of ^{207}PbO. The obtained hyperfine constants, A_\parallel = -3826 MHz for the a(1) state and A_\parallel = 4887 MHz for the B(1) state, are in very good agreement with the experimental data, -4113 MHz and 5000 \pm 200 MHz, respectively. We find W_d = -(6.1 ^{+1.8}_{-0.6}) 10^{24} Hz/(e cm) for a(1), and W_d = (8.0 \pm 1.6) 10^{24} Hz/(e cm) for B(1). The obtained values are analyzed and compared to recent relativistic coupled cluster results and a semiempirical estimate of W_d for the a(1) state.Comment: 6 pages, REVTeX4 style, submitted to Pthys.Rev.

Таргетная терапия распространенного рака почки Сутентом®: побочные эффекты и их коррекция

.

ИНТЕРМИТТИРУЮЩАЯ ГОРМОНАЛЬНАЯ ТЕРАПИЯ У БОЛЬНЫХ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ

Intermittent hormone therapy (IHT) is an effective and safe hormonal method in patients with prostate cancer (PC), which is as efficacious as continuous hormone therapy. IHT substantially improves quality of life at a therapy-free interval and reduces the cost of the performed therapy. IHT  Интермиттирующая гормональная терапия (ИГТ) является эффективным и безопасным методом гормонального воздействия у больных раком предстательной железы (РПЖ), эффективность которого не уступает постоянной гормональной терапии. Проведение ИГТ существенно улучшает качество жизни пациентов в период отсутствия терапии и снижает стоимость проводимого лечения. ИГТ может быть рекомендована при терапии больных РПЖ в различных клинических ситуациях, в том числе у пациентов с наличием отдаленных метастазов.

ПРИМЕНЕНИЕ ТАРГЕТНЫХ ПРЕПАРАТОВ В ЛЕЧЕНИИ МЕТАСТАТИЧЕСКОГО РАКА ПОЧКИ: ПОСЛЕДОВАТЕЛЬНОЕ НАЗНАЧЕНИЕ ИЛИ КОМБИНАЦИЯ

The development of molecular biology led to the discovery of major pathogenetic pathways in the development of renal cell carcinoma (RCC), contributing to the designing of novel drugs to treat metastatic RCC, which belong to a group of target agents or tyrosine kinase inhibitors. Phases II and III clinical trials have proven the efficacy and controlled safety profile of a broad range of drugs for the treatment of metastatic RCC. The developing resistance to drugs and their intolerance determine the need to conduct new clinical studies and to search for novel agents and treatment regimens to improve survival and quality of life in patients. The performed studies of the efficiency and safety of sequential use of antiangiogenic drugs and their combination have supported that it is expedient to apply these treatment policies to patients with metastatic RCC. The expected results from the ongoing large Phase III clinical trials will let one find out how to optimally use target agents, in what combination or in what sequence.Достижения молекулярной биологии позволили выяснить основные патогенетические пути развития почечно-клеточного рака (ПКР), что способствовало созданию новых препаратов для лечения метастатического ПКР, относящихся к группе таргетных препаратов или ингибиторов тирозинкиназы. В клинических исследованиях II и III фазы доказаны эффективность и управляемый профиль безопасности широкого спектра препаратов для лечения метастатического ПКР. Развивающаяся резистентность и непереносимость препаратов обусловливают необходимость в проведении новых клинических исследований, поиска новых препаратов и схем лечения, направленных на улучшение показателей выживаемости и качества жизни больных. Проведенные исследования по изучению эффективности и безопасности последовательного применения антиангиогенных препаратов и их комбинации подтвердили целесообразность использования этих стратегий лечения у больных метастатическим ПКР. Ожидаемые результаты продолжающихся крупных клинических исследований III фазы позволят выяснить, как оптимально использовать таргетные препараты, в какой комбинации или последовательности

Адъювантная гормональная терапия как метод радикального лечения у больных местно-распространенным раком предстательной железы

.